How should I manage a patient who abruptly stops long-term systemic glucocorticoids?

Management of Abrupt Glucocorticoid Discontinuation

If a patient has abruptly stopped long-term systemic glucocorticoids, immediately restart physiologic replacement dosing (equivalent to 4-6 mg prednisone daily) and assess for signs of adrenal crisis requiring emergent treatment with parenteral glucocorticoids and fluid resuscitation. 1

Immediate Assessment and Stabilization

Evaluate for Adrenal Crisis

Patients who abruptly discontinue glucocorticoids are at risk for life-threatening adrenal crisis. Consider adrenal crisis if the patient presents with hemodynamic instability, persistent vomiting, or diarrhea—treat immediately with parenteral glucocorticoids (100 mg hydrocortisone IV) and aggressive fluid resuscitation without waiting for laboratory confirmation. 1

Key clinical features suggesting adrenal insufficiency include:

• Hypotension or orthostatic symptoms
• Severe fatigue or weakness
• Nausea, vomiting, or abdominal pain
• Confusion or altered mental status
• Hypoglycemia

Restart Glucocorticoid Coverage

Once adrenal crisis is excluded or treated, restart glucocorticoids at physiologic replacement doses (hydrocortisone 15-25 mg daily in divided doses or prednisone 4-6 mg daily). Do not leave patients without glucocorticoid coverage if they were on long-term therapy, as HPA axis recovery is unpredictable and can take months. 1

Risk Stratification Based on Prior Exposure

Short-term Use (<3-4 weeks)

If the patient was on glucocorticoids for less than 3-4 weeks regardless of dose, HPA axis suppression is unlikely. These patients can remain off glucocorticoids without testing. 1

Long-term Use (≥3-4 weeks)

Assume glucocorticoid-induced adrenal insufficiency in any patient who received systemic glucocorticoids for ≥3-4 weeks and restart physiologic replacement. 1 This includes patients on:

• Oral glucocorticoids at any dose
• High-dose inhaled glucocorticoids (>1 year)
• Multiple glucocorticoid formulations simultaneously
• Intra-articular injections within the previous 2 months
• Concomitant CYP3A4 inhibitors 1

Distinguishing Adrenal Insufficiency from Glucocorticoid Withdrawal Syndrome

A critical pitfall is confusing glucocorticoid withdrawal syndrome (GWS) with true adrenal insufficiency—both present with fatigue, myalgias, arthralgias, and malaise, but GWS occurs despite adequate cortisol production. 1, 2

To differentiate: measure morning serum cortisol (8:00-9:00 AM, at least 24 hours after last glucocorticoid dose). 1

Interpretation:

• >300 nmol/L (>10 μg/dL): HPA axis recovered; symptoms are likely GWS—manage with reassurance and symptomatic treatment
• 150-300 nmol/L (5-10 μg/dL): Continue physiologic replacement; retest in weeks to months
• <150 nmol/L (<5 μg/dL): Confirmed adrenal insufficiency; continue physiologic replacement; retest in several months 1

Do not routinely perform ACTH stimulation testing—morning cortisol is sufficient for clinical decision-making. 1

Structured Tapering Plan After Stabilization

Once the patient is stabilized on physiologic replacement:

Step 1: Ensure Disease Control

Only attempt further tapering if the underlying condition requiring glucocorticoids is controlled and no longer requires treatment. 1

Step 2: Switch Long-Acting Agents

If the patient was on dexamethasone or betamethasone, switch to shorter-acting agents (hydrocortisone or prednisone) to facilitate HPA axis recovery. 1

Step 3: Choose Tapering Strategy

Option A (Clinical Monitoring):

• Gradually taper glucocorticoid dose while monitoring for symptoms of adrenal insufficiency
• If severe symptoms develop, temporarily increase to the previous tolerated dose and extend tapering duration
• This approach is appropriate when laboratory testing is not feasible or desired 1

Option B (Biochemical Confirmation):

• Continue physiologic replacement and measure morning cortisol periodically
• Only reduce dose when cortisol levels indicate HPA recovery (>300 nmol/L or >10 μg/dL)
• This approach provides objective confirmation but requires laboratory access 1

Step 4: Provide Stress Dosing Education

All patients with current or recent glucocorticoid use who have not had biochemical confirmation of HPA axis recovery must receive stress dose coverage during illness, surgery, or trauma. 1

• Minor stress (fever, dental work): Double or triple usual dose orally
• Major stress (surgery, severe illness): 100 mg hydrocortisone IV/IM followed by 50-100 mg every 6-8 hours 1

Special Circumstances Requiring Endocrinology Referral

Refer to endocrinology if: 1

• No HPA axis recovery after one year on physiologic replacement
• History of adrenal crisis
• Signs of exogenous Cushing syndrome (assume adrenal insufficiency in these patients) 1

Common Pitfalls to Avoid

1. Never assume HPA axis recovery without testing or adequate time off supraphysiologic doses—recovery varies greatly between individuals and can take 6-12 months or longer 1, 3

2. Do not use fludrocortisone—it is not indicated in glucocorticoid-induced adrenal insufficiency as mineralocorticoid function is preserved 1

3. Do not test for adrenal insufficiency while patients are still on supraphysiologic doses—results will be uninterpretable 1

4. Do not reduce below physiologic replacement doses (equivalent to 4-6 mg prednisone) until HPA axis recovery is documented, as this provides inadequate replacement while still suppressing endogenous production 1

The evidence strongly supports a cautious approach prioritizing patient safety, as abrupt discontinuation of long-term glucocorticoids carries significant morbidity and mortality risk from adrenal crisis. The 2024 European Society of Endocrinology/Endocrine Society joint guideline 1 provides the most comprehensive and recent framework for managing these complex patients.